| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.13 | 7e-05 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0005 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.003 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.13 | 0.004 |